BR9706387A - Derivados de purina substituìdos, processos para a sua preparação, seu emprego e composições contendo os mesmos - Google Patents

Derivados de purina substituìdos, processos para a sua preparação, seu emprego e composições contendo os mesmos

Info

Publication number
BR9706387A
BR9706387A BR9706387-8A BR9706387A BR9706387A BR 9706387 A BR9706387 A BR 9706387A BR 9706387 A BR9706387 A BR 9706387A BR 9706387 A BR9706387 A BR 9706387A
Authority
BR
Brazil
Prior art keywords
preparation
processes
same
compositions containing
purine derivatives
Prior art date
Application number
BR9706387-8A
Other languages
English (en)
Inventor
Anuschirwan Dr Peyman
Jochen Dr Knolle
Volkmar Dr Wehner
Gerhard Dr Breipohl
Jean-Francois Dr Gourvest
Denis Dr Carniato
Thomas Richard Dr Gadek
Original Assignee
Hoechst Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Genentech Inc filed Critical Hoechst Ag
Publication of BR9706387A publication Critical patent/BR9706387A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção:<B>"DERIVADOS DE PURINA SUBSTITUìDOS, PROCESSOS PARA A SUA PREPARAçãO, SEU EMPREGO E COMPOSIçõES CONTENDO OS MESMOS"<D>. A presente invenção refere-se a compostos das fórmulas I e Ia nas quais X,Y,W,W^ a^, G e G^ a^ têm os significados indicados nas reivindicações e seus sais toleráveis fisiologicamente e seus prodrugs, sua preparação, seu emprego, especialmente como compostos ativos farmacêuticos e preparações farmacêuticas contendo os mesmos. Os compostos da fórmula 1 são antagonistas do receptor de vitronectin e podem ser empregados, por exemplo, como inibidores da reabsorção dos ossos e para tratametno da osteoporose.
BR9706387-8A 1996-12-20 1997-12-17 Derivados de purina substituìdos, processos para a sua preparação, seu emprego e composições contendo os mesmos BR9706387A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653646A DE19653646A1 (de) 1996-12-20 1996-12-20 Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung

Publications (1)

Publication Number Publication Date
BR9706387A true BR9706387A (pt) 2000-03-14

Family

ID=7815761

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9706387-8A BR9706387A (pt) 1996-12-20 1997-12-17 Derivados de purina substituìdos, processos para a sua preparação, seu emprego e composições contendo os mesmos

Country Status (22)

Country Link
EP (1) EP0853084B1 (pt)
JP (1) JP4620190B2 (pt)
KR (1) KR19980064655A (pt)
CN (2) CN1101816C (pt)
AR (1) AR010700A1 (pt)
AT (1) ATE404562T1 (pt)
AU (1) AU728865B2 (pt)
BR (1) BR9706387A (pt)
CA (1) CA2225366C (pt)
CZ (1) CZ294437B6 (pt)
DE (2) DE19653646A1 (pt)
HK (1) HK1012190A1 (pt)
HU (1) HUP9702507A3 (pt)
ID (1) ID19254A (pt)
IL (1) IL122642A0 (pt)
NO (1) NO314583B1 (pt)
NZ (1) NZ329431A (pt)
PL (1) PL323969A1 (pt)
RU (1) RU2228335C2 (pt)
TR (1) TR199701647A3 (pt)
TW (1) TW523515B (pt)
ZA (1) ZA9711317B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420558B1 (en) 1998-04-09 2002-07-16 Meiji Seika Kaisha, Ltd. Aminopiperidine derivates as integrin αvβ3 antagonists
CZ20012320A3 (cs) 1998-12-23 2002-10-16 G. D. Searle & Co. Léčivo s obsahem inhibitoru cyklooxygenázy-2 a jednoho nebo více antineoplastických činidel pro kombinační terapii při léčení neoplasie
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
WO2001010844A1 (en) 1999-08-05 2001-02-15 Meiji Seika Kaisha, Ltd. φ-AMINO-α-HYDROXYCARBOXYLIC ACID DERIVATIVES HAVING INTEGRIN αvβ3 ANTAGONISM
EP1176145A1 (en) * 2000-07-28 2002-01-30 Aventis Pharma Deutschland GmbH Novel guanidino derivatives as inhibitors of cell adhesion
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
KR100438820B1 (ko) * 2001-03-05 2004-07-05 삼성코닝 주식회사 Ιιι-ⅴ족 화합물 반도체 기판의 제조 방법
US20040136949A1 (en) 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
MX2009007597A (es) 2007-01-18 2009-07-22 Merck Patent Gmbh Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
WO2009048072A1 (ja) 2007-10-11 2009-04-16 Daiichi Sankyo Company, Limited 破骨細胞関連蛋白質Ｓｉｇｌｅｃ－１５を標的とした抗体
NZ586129A (en) * 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
MY152033A (en) 2009-04-09 2014-08-15 Daiichi Sankyo Co Ltd Anti-siglec-15 antibody
BRPI1011206A2 (pt) 2009-05-25 2016-03-15 Merck Patent Gmbh administração contínua de ligantes de integrina para tratar câncer
TW201219568A (en) 2010-10-05 2012-05-16 Daiichi Sankyo Co Ltd Antibody targeting osteoclast-related protein Siglec-15
TW201343672A (zh) 2012-03-30 2013-11-01 Daiichi Sankyo Co Ltd Ｃｄｒ經修飾之抗ｓｉｇｌｅｃ－１５抗體
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4730696Y1 (pt) * 1966-12-10 1972-09-13
JPS6396663A (ja) * 1986-10-13 1988-04-27 Mita Ind Co Ltd 静電荷像現像用トナ−
JPS6396553A (ja) * 1986-10-14 1988-04-27 Sekisui Chem Co Ltd 充填剤
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
MX9207334A (es) * 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
FR2700337B1 (fr) * 1993-01-11 1995-04-14 Lafon Labor Dérivés d'imidazopyridine-2-one, leur procédé de préparation et leur utilisation en thérapeutique.
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
WO1996000730A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
AU4729796A (en) * 1994-12-28 1996-07-19 Peter E. Nielsen Peptide nucleic acid incorporating a chiral backbone
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
JP2001518054A (ja) * 1995-06-07 2001-10-09 パーセプティブ バイオシステムズ，インコーポレーテッド Ｐｎａ−ｄｎａキメラと、このキメラ合成用のｐｎａシントン
JPH1025294A (ja) * 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
CA2249598A1 (en) * 1996-03-26 1997-10-02 Paul Joseph Gilligan Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
ATE311402T1 (de) * 1996-07-24 2005-12-15 Buchardt Dorte Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2

Also Published As

Publication number Publication date
CN1101816C (zh) 2003-02-19
IL122642A0 (en) 1998-08-16
NO975977L (no) 1998-06-22
JPH10182645A (ja) 1998-07-07
EP0853084A3 (de) 1998-09-09
TR199701647A2 (xx) 1998-07-21
DE59712958D1 (de) 2008-09-25
HU9702507D0 (en) 1998-03-02
CA2225366C (en) 2006-10-10
AR010700A1 (es) 2000-06-28
CA2225366A1 (en) 1998-06-20
JP4620190B2 (ja) 2011-01-26
NO314583B1 (no) 2003-04-14
PL323969A1 (en) 1998-06-22
HUP9702507A3 (en) 1999-12-28
NZ329431A (en) 2000-01-28
MX9710277A (es) 1998-10-31
AU4846697A (en) 1998-06-25
TR199701647A3 (tr) 1998-07-21
AU728865B2 (en) 2001-01-18
RU2228335C2 (ru) 2004-05-10
CN1193623A (zh) 1998-09-23
HK1012190A1 (en) 1999-07-30
HUP9702507A2 (hu) 1999-05-28
CZ294437B6 (cs) 2005-01-12
ZA9711317B (en) 1998-06-22
KR19980064655A (ko) 1998-10-07
TW523515B (en) 2003-03-11
EP0853084A2 (de) 1998-07-15
EP0853084B1 (de) 2008-08-13
ATE404562T1 (de) 2008-08-15
CN1495184A (zh) 2004-05-12
ID19254A (id) 1998-06-28
NO975977D0 (no) 1997-12-19
DE19653646A1 (de) 1998-06-25
CZ411497A3 (cs) 1998-07-15

Similar Documents

Publication Publication Date Title
BR9706387A (pt) Derivados de purina substituìdos, processos para a sua preparação, seu emprego e composições contendo os mesmos
BR9814308A (pt) Derivados de acilguanidina como inibidores de ressorção óssea e como antagonistas de receptores de vitronectina
BRPI9810519A (pt) derivados de 4&#39;&#39;-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR9810097A (pt) Derivados de macrolìdeos c-4-substituìdos
MX9504630A (es) Nuevos derivados de la oxazolidinona, antagonista del receptor de adhesion, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
BR9907735A (pt) Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular
BR0116237A (pt) Compostos, composições farmacêuticas, uso de qualquer um ou mais compostos, e, processo para a manufatura de composições farmacêuticas
ES2102475T3 (es) Nuevas alquil-amidas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
BR9706386A (pt) Antagonistas do receptor de vitronectina, sua preparação e seu us0
BR9801150A (pt) Derivados de propanolamina, processos para a preparação deles, produtos farmacêuticos compreendendo esses compostos e uso dos mesmos.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
BR0210548A (pt) éteres aromáticos substituìdos como inibidores do transporte de glicina e composição farmacêutica aque os compreende
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
IL144725A0 (en) Novel guanidine derivatives as inhibitors of cell adhesion
BR0214141A (pt) Derivados de piperidina e seu uso como moduladores da atividade de receptor de quimiocina (especialmente ccr5)
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas
BR0012129A (pt) Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os
YU89701A (sh) Substituisani derivati purina kao inhibitori adhezije ćelije
HUP0202710A2 (hu) Vitronektin receptor antagonisták, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0104533A2 (hu) Új pirimidinszármazékok és eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: C07D 473/34, A61K 32/52, A61P 3/00, A61P 9/00, A61P 13/12, A61P 19/10, A61P 29/00, A61P 3500

Ipc: C07D 473/34 (2007.01), A61K 31/52 (2007.01), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ARTIGO 8O DA LPI